Retinalamin: The Retinal Polypeptide Bioregulator and What Its Trial Evidence Actually Shows

This article is for educational purposes and is intended for healthcare practitioners and informed readers. It does not constitute medical advice or therapeutic guidance. Retinalamin is a registered prescription medicine in Russia, administered by injection under medical supervision. It is not approved as a therapeutic good in Australia and is not a naturopathic protocol that can be sourced or self-administered.

1. What Retinalamin Is: and Is Not

Retinalamin is often mentioned alongside Vladimir Khavinson's short-peptide bioregulators, but like Cortexin, it belongs to a different category from a single defined peptide such as Epitalon or Pinealon. Retinalamin is a polypeptide preparation: a complex of water-soluble polypeptide fractions extracted from the retinal tissue of cattle eyes, with a molecular weight of no more than 10,000 daltons per fraction. According to the manufacturer's product information, each vial contains 5 mg of this polypeptide complex with glycine added as a stabiliser.

The manufacturer, GEROPHARM (the registered holder of Retinalamin in Russia), classifies it pharmacotherapeutically as a stimulator of tissue regeneration, and it is dispensed as a lyophilisate reconstituted for intramuscular or parabulbar (periocular) injection, not as an oral supplement.

For the broader category these tissue-derived and synthetic bioregulators sit within, see the peptide bioregulators overview.

2. Proposed Mechanism

Retinalamin's proposed mechanism, as described in the manufacturer's own product information, centres on restoring the functional relationship between the retinal pigment epithelium and the outer segments of photoreceptors, the layer where light-sensing and metabolic support between these two cell types occurs. The manufacturer describes the preparation as normalising vascular permeability in ocular tissue, limiting oxidative stress and glutamate-driven excitotoxicity, and supporting Müller glial cell activity and lipid peroxidation control.

This is a plausibility account from the manufacturer rather than an independent mechanistic study, and it should be read that way. The broader research tradition it sits within is Khavinson's proposal that short and low-molecular-weight tissue peptides can enter cell nuclei and interact with chromatin to influence tissue-specific gene expression, summarised in a 2021 systematic review in Molecules by Khavinson and colleagues, which describes peptides of two to seven amino acids modulating DNA methylation and transcription-factor accessibility across multiple tissue types (PMID 34834147). That review is a general framework paper; it does not study Retinalamin specifically, and no equivalent nucleus- or chromatin-level mechanistic study naming Retinalamin has been located.

3. Clinical Evidence

Retinalamin's published clinical evidence is limited to a small number of Russian-language ophthalmology studies, and the picture is complicated by the fact that its best-documented trial did not test it alone.

3.1 Diabetic retinopathy, as part of a combination regimen

The most frequently cited study is Trofimova and Khavinson's 2001 paper in Vestnik Oftalmologii, which evaluated a combination of three bioregulator preparations, retinalamin (retinal), epithalamin (pineal), and cortexin (cerebral cortex), in 104 patients with diabetic retinopathy against 42 untreated controls. The authors reported improved visual acuity in roughly 90% of treated cases, improvement in the ophthalmoscopic appearance of the fundus (resolution of haemorrhages and reduced macular oedema), improved retinal blood flow and function, normalised blood glucose handling, and no adverse effects (PMID 11521426).

This is a genuine, PubMed-indexed clinical finding, but it is not a Retinalamin monotherapy result. Three different bioregulator preparations were given together, so this study cannot isolate what Retinalamin itself contributed to the outcome, and nothing in the available abstract indicates the comparison was randomised or blinded.

3.2 Glaucoma, as a single preparation across three delivery routes

A more recent and more directly relevant study is Erichev, Lovpache, and Yaremenko's 2020 paper, also in Vestnik Oftalmologii, which tested Retinalamin alone (a total dose of 50 mg) in 498 patients with open-angle glaucoma and controlled intraocular pressure, comparing three delivery routes: combined intramuscular plus retrobulbar injection, retrobulbar injection alone, and intramuscular injection alone (PMID 32366071). Retinal sensitivity and visual field responses were assessed at baseline, three months, and six months. The authors reported measurable gains in retinal sensitivity across all three delivery routes, with the largest improvements in early-to-moderate-stage glaucoma, and stated the benefit was best sustained at six months in the retrobulbar-only group. Visual acuity itself remained stable across all groups. This was a study of retinal sensitivity and functional response, not a change in how well patients could see on a standard eye chart.

This is the strongest single-preparation evidence for Retinalamin currently indexed, but it is still an open, non-placebo-controlled comparison of delivery routes rather than a trial against an inactive control.

4. Evidence Quality: An Honest Accounting

• The headline trial is a combination study. The 90%-improvement figure most often quoted for Retinalamin comes from a three-preparation regimen, not Retinalamin used alone, and should not be read as a Retinalamin-specific effect size.
• The single-preparation trial has no untreated arm. The 2020 glaucoma study compares delivery routes for Retinalamin against each other, not Retinalamin against placebo or standard care alone.
• Design is open-label, not blinded. Neither available abstract describes randomisation or masking, the standard needed to rule out observer and expectation effects in outcomes like fundus appearance and visual field testing.
• Route of administration. Retinalamin is given by intramuscular or retrobulbar (periocular) injection under medical supervision in Russia, not orally, and is not something a naturopathic practitioner administers or a patient self-sources.
• Geographic and source concentration. Both clinical papers are Russian-language, published in the same journal, and involve the Khavinson research tradition; no independent replication outside that tradition, and no registration on ClinicalTrials.gov, has been located.
• Regulatory status. Retinalamin is a registered prescription medicine in Russia but is not an approved therapeutic good in Australia, the United States, or most Western jurisdictions.

The honest position is that Retinalamin has real, PubMed-indexed clinical data behind it, more than most bioregulator peptides can claim. That data is small in volume, geographically narrow, methodologically open-label, and in its most-cited form confounded by co-administration with two other preparations.

5. Research Context

Retinalamin is best understood as the retina-targeted member of the tissue-extract polypeptide preparations, structurally analogous to Cortexin (brain) rather than to single synthetic tripeptides such as Epitalon or Vesugen. For the wider category, the proposed chromatin-interaction framework, and an assessment of evidence quality across the bioregulator family, see the peptide bioregulators overview.

Frequently Asked Questions

What is Retinalamin made of?

Retinalamin is a complex of water-soluble polypeptide fractions extracted from the retinal tissue of cattle eyes, with a molecular weight of no more than 10,000 daltons per fraction, formulated with glycine as a stabiliser. It is a mixture of many peptide components, not a single defined molecule.

What is Retinalamin used for?

In Russia, where it is registered and manufactured by GEROPHARM, Retinalamin is prescribed for diabetic retinopathy, glaucoma, and other conditions involving retinal damage. It is given by intramuscular or retrobulbar injection under medical supervision, not taken orally.

Does the research show Retinalamin actually works?

There are two PubMed-indexed clinical studies. One reported improved visual acuity in about 90% of diabetic retinopathy patients, but as part of a three-preparation combination regimen rather than Retinalamin alone. The other tested Retinalamin alone across three injection routes in glaucoma patients and reported gains in retinal sensitivity, best sustained with retrobulbar delivery, but without a placebo control arm. Both studies were open-label.

Is Retinalamin available or approved in Australia?

No. Retinalamin is not an approved therapeutic good in Australia. It is a Russian prescription medicine administered by injection under specialist medical supervision there, and is not part of naturopathic practice.

How does Retinalamin differ from synthetic bioregulator peptides like Epitalon?

Epitalon and similar Khavinson compounds are single, defined synthetic peptides of a few amino acids. Retinalamin, like Cortexin, is a complex mixture of many tissue-derived polypeptides rather than one molecule, which affects both how it is thought to work and how consistently it can be standardised between batches.

References

Trofimova SV, Khavinson VKh. Effectiveness of bio-regulators in the treatment of diabetic retinopathy. Vestn Oftalmol. 2001;117(3):11-4 (PMID 11521426). Erichev VP, Lovpache DN, Yaremenko TV. Peptide bioregulators: delivery and efficacy. Vestn Oftalmol. 2020;136(2):56-62 (PMID 32366071). Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053 (PMID 34834147). Retinalamin product and mechanism information: GEROPHARM official manufacturer page (https://geropharm.com/portfolio/oftalymologiya/retinalamin). Open-label clinical data and manufacturer mechanism claims should not be equated with independent, placebo-controlled evidence.